ECSP14017586A - Derivados de tetrahidro-quinazolinona - Google Patents
Derivados de tetrahidro-quinazolinonaInfo
- Publication number
- ECSP14017586A ECSP14017586A ECIEPI201417586A ECPI201417586A ECSP14017586A EC SP14017586 A ECSP14017586 A EC SP14017586A EC IEPI201417586 A ECIEPI201417586 A EC IEPI201417586A EC PI201417586 A ECPI201417586 A EC PI201417586A EC SP14017586 A ECSP14017586 A EC SP14017586A
- Authority
- EC
- Ecuador
- Prior art keywords
- tetrahydro
- quinazolinone derivatives
- diseases
- tankirase
- inflammation
- Prior art date
Links
- TYNNEEKKMHSZMO-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-1h-quinazolin-2-one Chemical class C1C=CC=C2NC(=O)NCC21 TYNNEEKKMHSZMO-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de la fórmula I (ver archivo de imágenes) en donde U, V y W tienen los significados indicados en la reivindicación 1, son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000841 | 2012-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14017586A true ECSP14017586A (es) | 2015-09-30 |
Family
ID=47628092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201417586A ECSP14017586A (es) | 2012-02-09 | 2014-09-05 | Derivados de tetrahidro-quinazolinona |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9339503B2 (es) |
| EP (1) | EP2812323B1 (es) |
| JP (1) | JP6116592B2 (es) |
| KR (1) | KR20140121477A (es) |
| CN (1) | CN104093714B (es) |
| AR (1) | AR089944A1 (es) |
| AU (1) | AU2013218357B2 (es) |
| BR (1) | BR112014019357A8 (es) |
| CA (1) | CA2863991C (es) |
| CL (1) | CL2014002097A1 (es) |
| CO (1) | CO7020919A2 (es) |
| DK (1) | DK2812323T3 (es) |
| EA (1) | EA026611B1 (es) |
| EC (1) | ECSP14017586A (es) |
| ES (1) | ES2579980T3 (es) |
| HR (1) | HRP20160735T1 (es) |
| HU (1) | HUE029717T2 (es) |
| IL (1) | IL233984A (es) |
| MX (1) | MX349736B (es) |
| NZ (1) | NZ630170A (es) |
| PE (1) | PE20141823A1 (es) |
| PH (1) | PH12014501581A1 (es) |
| PL (1) | PL2812323T3 (es) |
| PT (1) | PT2812323T (es) |
| RS (1) | RS55377B1 (es) |
| SG (1) | SG11201404654SA (es) |
| SI (1) | SI2812323T1 (es) |
| TW (1) | TWI572593B (es) |
| UA (1) | UA116627C2 (es) |
| WO (1) | WO2013117288A1 (es) |
| ZA (1) | ZA201406579B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2822656B1 (en) | 2012-03-07 | 2016-10-19 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014102817A1 (en) | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| BR112016008994A2 (pt) * | 2013-11-07 | 2017-09-19 | Lilly Co Eli | Compostos de pirido[2,3-d]pirimidin-4-ona como inibidores de tanquirase |
| CN106243088B (zh) | 2015-06-03 | 2019-01-04 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
| KR101777475B1 (ko) * | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| NZ749946A (en) | 2016-06-30 | 2023-11-24 | Yakult Honsha Kk | Novel compound or pharmaceutically acceptable salt thereof |
| CN108727302A (zh) * | 2017-10-23 | 2018-11-02 | 科迈化工股份有限公司 | 一种环保型n-叔丁基-2-苯并噻唑次磺酰胺（ns）合成工艺 |
| JP7369968B2 (ja) * | 2017-12-27 | 2023-10-27 | 公益財団法人がん研究会 | 抗がん剤 |
| ES2998084T3 (en) | 2017-12-27 | 2025-02-19 | Japanese Found For Cancer Res | Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor |
| BR112021002772A2 (pt) | 2018-08-16 | 2021-05-04 | F. Hoffmann-La Roche Ag | compostos, composições farmacêuticas, método de tratamento de câncer, métodos para regular a atividade de uma proteína, para inibir a proliferação de uma população de células, para tratar um distúrbio, para preparar uma proteína, para inibir metástase de tumor e para tratamento de câncer e usos |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| CA2410562A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| AUPR975601A0 (en) * | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| KR101286969B1 (ko) * | 2004-06-30 | 2013-07-23 | 얀센 파마슈티카 엔.브이. | Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체 |
| EP1856061B1 (en) * | 2005-03-11 | 2011-01-26 | Merck Patent GmbH | Tetrahydro- and dihydroquinazolinones |
| SI2134691T1 (sl) * | 2007-03-08 | 2012-06-29 | Janssen Pharmaceutica Nv | Derivati kvinolina kot PARP in TANK inhibitorji |
| WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| WO2011111880A1 (ko) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
-
2013
- 2013-01-14 EP EP13701703.4A patent/EP2812323B1/en active Active
- 2013-01-14 JP JP2014555963A patent/JP6116592B2/ja active Active
- 2013-01-14 PT PT137017034T patent/PT2812323T/pt unknown
- 2013-01-14 HU HUE13701703A patent/HUE029717T2/en unknown
- 2013-01-14 ES ES13701703.4T patent/ES2579980T3/es active Active
- 2013-01-14 KR KR1020147024967A patent/KR20140121477A/ko not_active Ceased
- 2013-01-14 WO PCT/EP2013/000078 patent/WO2013117288A1/en not_active Ceased
- 2013-01-14 BR BR112014019357A patent/BR112014019357A8/pt not_active Application Discontinuation
- 2013-01-14 CN CN201380008647.2A patent/CN104093714B/zh active Active
- 2013-01-14 EA EA201400879A patent/EA026611B1/ru not_active IP Right Cessation
- 2013-01-14 DK DK13701703.4T patent/DK2812323T3/en active
- 2013-01-14 HR HRP20160735TT patent/HRP20160735T1/hr unknown
- 2013-01-14 UA UAA201409705A patent/UA116627C2/uk unknown
- 2013-01-14 SI SI201330228A patent/SI2812323T1/sl unknown
- 2013-01-14 AU AU2013218357A patent/AU2013218357B2/en active Active
- 2013-01-14 US US14/378,009 patent/US9339503B2/en active Active
- 2013-01-14 MX MX2014009491A patent/MX349736B/es active IP Right Grant
- 2013-01-14 SG SG11201404654SA patent/SG11201404654SA/en unknown
- 2013-01-14 CA CA2863991A patent/CA2863991C/en active Active
- 2013-01-14 PE PE2014001242A patent/PE20141823A1/es not_active Application Discontinuation
- 2013-01-14 PL PL13701703.4T patent/PL2812323T3/pl unknown
- 2013-01-14 NZ NZ630170A patent/NZ630170A/en not_active IP Right Cessation
- 2013-01-14 RS RS20160507A patent/RS55377B1/sr unknown
- 2013-02-08 TW TW102105039A patent/TWI572593B/zh not_active IP Right Cessation
- 2013-02-08 AR ARP130100401A patent/AR089944A1/es unknown
-
2014
- 2014-07-09 PH PH12014501581A patent/PH12014501581A1/en unknown
- 2014-07-30 CO CO14165918A patent/CO7020919A2/es unknown
- 2014-08-06 IL IL233984A patent/IL233984A/en active IP Right Grant
- 2014-08-07 CL CL2014002097A patent/CL2014002097A1/es unknown
- 2014-09-05 EC ECIEPI201417586A patent/ECSP14017586A/es unknown
- 2014-09-08 ZA ZA2014/06579A patent/ZA201406579B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| CL2017000290A1 (es) | Inhibidores de la proteína kinasa c y métodos de su uso. | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX377384B (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| NI201500140A (es) | Compuestos y composiciones terapéuticos | |
| MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| UY35633A (es) | Inhibidores de bromodominios | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| MX359656B (es) | Derivados de oxoquinazolinil-butanamida. | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CL2015001246A1 (es) | Derivados de bendamustina y los metodos de su uso | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. |